Lonza: expansion at Oregon site
Lonza has announced plans to invest in expansion of its particle engineering and drug product capabilities at its site in Bend, Oregon, in order to meet increased market demand. The project—which will include new suites for the development and clinical manufacture of drug product intermediates and drug products utilizing spray-drying, hot-melt extrusion and melt-spray-congeal processing—is expected to be completed by May 2022.
Paul Granberry, managing director for Lonza Bend, said, “We continue to see increased demand for development, clinical and commercial manufacture of particle-engineered intermediates and finished drug products. Dedicated, fit-for-purpose suites, infrastructure and systems are critical for supporting the needs of our customers’ early-phase programs.”
